Combination of anti CD19 antibody with BCL-2 inhibitor and uses thereof

A synergistic combination of an anti-CD19 antibody and venetoclax targets CD19-expressing B cells, addressing the limitations of current treatments by enhancing cell killing efficacy in non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.

JP2024167208AInactive Publication Date: 2024-12-03MORFOZIS AG
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024125584
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2016-10-28
Filing Date
2024-08-01
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia, such as those targeting the CD20 antigen or using BCL-2 inhibitors, have limited efficacy and often result in relapse, with many B cells not expressing CD20 and thus not being treatable.

Method used

A synergistic combination of an anti-CD19 antibody, specifically MOR00208, and a BCL-2 inhibitor like venetoclax is used to target and kill CD19-expressing B cells, leveraging their synergistic effect to enhance treatment efficacy.

Benefits of technology

The combination of anti-CD19 antibody and venetoclax demonstrates synergistic cell killing in vitro and in vivo models, indicating potential for improved treatment outcomes in non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167208000001_ABST
    Figure 2024167208000001_ABST
Patent Text Reader

Abstract

To provide the use of a CD19-specific antibody in the production of pharmaceuticals for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia, and a pharmaceutical combination for the treatment.SOLUTION: The present invention provides the use of a CD19-specific antibody, comprising HCDR1-HCDR3 regions comprising specific sequences and LCDR1-LCDR3 regions comprising specific sequences, in the production of pharmaceuticals for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia, where the CD19-specific antibody is used in combination with a BCL-2 inhibitor.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to pharmaceutical combinations of anti-CD19 antibodies and BCL-2 inhibitors for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia. [Background technology]

[0002] B cells are lymphocytes that play a major role in humoral immune responses. B cells are produced in the bone marrow of most mammals and represent 5-15% of the circulating lymphocyte pool. The main function of B cells is to make antibodies against various antigens, making them an essential component of the adaptive immune system.

[0003] Due to their critical role in regulating the immune system, dysregulation of B cells is associated with a variety of disorders such as lymphomas and leukemias, including non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).

[0004] NHL is a heterogeneous malignant tumor arising from lymphocytes. The incidence in the United States (US) is estimated at 65,000 cases per year, with approximately 20,000 deaths (American Cancer Society, 2006; and SEER Cancer Statistics Review). The disease can occur at any age, with onset usually beginning in adults over 40 years of age, and incidence increasing with age. NHL is characterized by the clonal proliferation of lymphocytes that accumulate in lymph nodes, blood, bone marrow, and spleen, although any major organ may be involved. The current classification system used by pathologists and clinicians is the World Health Organization Classification of Tumours, which groups NHL into precursor and mature B-cell or mature T-cell neoplasms. PDQ currently classifies NHL as indolent or aggressive for inclusion in clinical trials. The low-grade NHL group consists mainly of follicular subtype, small lymphocytic lymphoma, MALT (mucosa-associated lymphoid tissue) and marginal zone, with low-grade encompassing approximately 50% of newly diagnosed B-cell NHL patients. High-grade NHL includes patients with histologically diagnosed diffuse large B-cell (DLBL, DLBCL or DLCL) (40% of all newly diagnosed patients have diffuse large cell), Burkitt cell and mantle cell. The clinical course of NHL is highly variable. The major determinant of clinical course is the histological subtype. Most low-grade NHLs are considered incurable diseases. Patients respond initially to either chemotherapy or antibody therapy, but the majority relapse. Studies to date have not demonstrated improved survival with early intervention. In asymptomatic patients, "watch and wait" is acceptable until the patient becomes symptomatic or the rate of disease progression appears to be accelerating. The disease may transform to more aggressive histology over time. Median survival is 8-10 years, and patients with indolent disease often undergo three or more lines of therapy during the course of their disease. Initial treatment for symptomatic indolent NHL patients has historically been combination chemotherapy.The most commonly used drugs include cyclophosphamide, vincristine, and prednisone (CVP); or cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP). Approximately 70%-80% of patients respond to these initial chemotherapy regimens, with periods of remission lasting approximately 2-3 years. The majority of patients eventually relapse. The discovery and clinical use of the anti-CD20 antibody, rituximab, has significantly improved response and survival rates. The current standard of care for most patients is rituximab plus CHOP (R-CHOP) or rituximab plus CVP (R-CVP). Interferon has been approved for initial treatment of NHL in combination with alkylating agents, but its use is limited in the United States. Rituximab therapy has been shown to be effective in several types of NHL and is currently approved as first-line treatment for both low-grade (follicular lymphoma) and high-grade NHL (diffuse large B-cell lymphoma). However, anti-CD20 monoclonal antibodies (mAbs) have significant limitations, including primary resistance (50% response in relapsed low-grade patients), acquired resistance (50% response rate upon retreatment), rare complete responses (2% complete response rate in the relapsed population), and continued relapse patterns. Finally, many B cells do not express CD20, and therefore many B-cell disorders cannot be treated with anti-CD20 antibody therapy.

[0005] In addition to NHL, there are several types of leukemia that result from dysregulation of B cells. Chronic lymphocytic leukemia (also called "chronic lymphocytic leukemia" or "CLL") is a type of adult leukemia caused by abnormal accumulation of B lymphocytes. In CLL, malignant lymphocytes may appear normal and mature, but are unable to fight infections efficiently. CLL is the most common form of leukemia in adults. Men are twice as likely to develop CLL than women. However, a significant risk factor is age. More than 75% of new cases are diagnosed in patients over 50 years of age. More than 10,000 cases are diagnosed each year, with almost 5,000 deaths annually (American Cancer Society, 2006; and SEER Cancer Statistics Review). CLL is an incurable disease, but it progresses slowly in most cases. Many people with CLL lead normal, active lives for many years. Early CLL is generally not treated due to its slow onset, as early intervention is not believed to improve survival time or quality of life. Instead, the condition is monitored over time. Initial CLL treatment varies depending on the exact diagnosis and progression of the disease. There are dozens of drugs used in CLL therapy. Combination chemotherapy regimens, such as FCR (Fludarabine, Cyclophosphamide, and Rituximab) and BR (Ibrutinib and Rituximab), are effective for both newly diagnosed and relapsed CLL. Allogeneic bone marrow (stem cell) transplantation is rarely used as a first-line treatment for CLL due to its risks.

[0006] Another type of leukemia is acute lymphoblastic leukemia (ALL), also called acute lymphocytic leukemia. ALL is characterized by the overproduction and continuous proliferation of malignant immature white blood cells (also called lymphoblasts) in the bone marrow. "Acute" refers to the undifferentiated, immature state of the circulating lymphocytes ("blasts") and the rapid progression of the disease, with a life expectancy of only a few weeks to a few months if left untreated. ALL is most common in childhood, with a peak incidence between 4 and 5 years of age. Children aged 12 to 16 years are more likely to die from ALL than children of other ages. Currently, at least 80% of childhood ALL is considered curable. Fewer than 4,000 cases are diagnosed each year, with nearly 1,500 deaths annually (American Cancer Society, 2006; and SEER Cancer Statistics Review).

[0007] The human CD19 molecule is a structurally distinct cell surface receptor expressed on the surface of human B cells, including, but not limited to, pre-B cells, early developmental B cells (i.e., immature B cells), mature B cells that undergo terminal differentiation to become plasma cells, and malignant B cells. CD19 is expressed on most pre-B acute lymphoblastic leukemias (ALL), non-Hodgkin's lymphomas, B-cell chronic lymphocytic leukemia (CLL), prolymphocytic leukemia, hairy cell leukemia, conventional acute lymphocytic leukemia, and some null cell acute lymphoblastic leukemias (Nadler et al, J. Immunol., 131:244-250 (1983), Loken et al, Blood, 70:1316-1324 (1987), Uckun et al, Blood, 71:13-29 (1988), Anderson et al, 1984. Blood, 63:1424-1433 (1984), Scheuermann, Leuk. Lymphoma, 18:385-397 (1995)). Expression of CD19 on plasma cells further suggests that CD19 can be expressed on differentiated B cell tumors such as multiple myeloma, plasmacytoma, and Waldenstrom's tumor (Grossbard et al., Br. J. Haematol, 102:509-15 (1998); Treon et al, Semin. Oncol, 30:248-52 (2003)).

[0008] Thus, the CD19 antigen is an immunotherapeutic target in the treatment of non-Hodgkin's lymphoma (including each of the subtypes described herein), chronic lymphocytic leukemia, and / or acute lymphoblastic leukemia.

[0009] Several CD19 therapies have been demonstrated. T cells expressing anti-CD19 chimeric antigen receptors (CARs) containing both CD3-zeta and 4-BB costimulatory domains have been administered to patients with advanced CLL. Kalos et al., T cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia, Science Translational Medicine, vol. 3, no. 95 (10 August 2011), which is incorporated by reference in its entirety. Sadelain et al., The promise and potential pitfalls of chimeric antigen receptors, Current Opinion in Immunology, Elsevier, vol. 21, no. 2, 2 April 2009, which is incorporated by reference in its entirety, also describe anti-CD19 chimeric antigen receptors (CARs). However, neither Kalos et al. nor Sadelain et al. describe antibodies specific for CD19 in combination with BCL-2 inhibitors as exemplified herein.

[0010] The use of CD19 antibodies in non-specific B cell lymphoma is discussed in WO2007076950 (US2007154473), both of which are incorporated by reference in their entireties, with a cursory mention of ibrutinib in a long list of possible combination partners, but does not teach the antibodies exemplified herein, nor does it suggest the synergistic effects of the combination in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia as exemplified herein.

[0011] The use of CD19 antibodies in CLL, NHL and ALL is described in Scheuermann et al., CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy, Leukemia and Lymphoma, Vol. 18, 385-397 (1995), which is incorporated by reference in its entirety, but does not suggest the combinations exemplified herein.

[0012] Additional antibodies specific for CD19 are described in WO 2005012493 (U.S. Patent No. 7,109,304), WO 2010053716 (U.S. Patent Application Publication No. 12 / 266,999) (Immunomedics); WO 2007002223 (U.S. Patent No. 8,097,703) (Medarex); WO 2007002223 (U.S. Patent No. 8,097,703) (Medarex); No. 008022152 (U.S. Patent Application Publication No. 12 / 377,251) and WO 2008150494 (Xencor), WO 2008031056 (U.S. Patent Application Publication No. 11 / 852,106) (Medimmune); WO 2007076950 (U.S. Patent Application Publication No. 11 / 648,505) (Merck Patent GmbH); WO 2009 / 052431 (U.S. Patent Application Publication No. 12 / 253,895) (Seattle Genetics); and WO 2010095031 (U.S. Patent Application Publication No. 12 / 710,442) (Glenmark Pharmaceuticals), WO 2012010562 and WO 2012010561 (International Drug Development), WO 2011147834 (Roche Glycart), and WO 2012 / 156455 (Sanofi).

[0013] Combinations of antibodies specific for CD19 and other drugs are described in WO 2010151341 (U.S. Patent Application Publication No. 13 / 377,514) (The Feinstein Institute); U.S. Patent No. 5,686,072 (University of Texas) and WO 2002022212 (Int. Appl. PCT / U.S. Patent Application Publication No. 01 / 29026) (IDEC Pharmaceuticals), WO 2013 / 024097 (U.S. Patent Application Publication No. 14 / 126,928) (MorphoSys AG) and WO 2013 / 024095 (U.S. Patent Application Publication No. 14 / 127,217) (MorphoSys AG), which are incorporated by reference in their entireties.

[0014] Several BCL-2 inhibitors are available on the market. VENCLEXTA™ (venetoclax), also known as GDC-0199, ABT-199 and RG7601, is a BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p who have received at least one prior therapy, as found by FDA-approved trials. Venetoclax is described in U.S. Patent Nos. 8,546,399 and 9,174,982, all of which are incorporated by reference in their entirety.

[0015] Despite recent advances in the discovery and development of anti-cancer drugs, many forms of cancer associated with CD19-expressing tumors still have poor prognoses. Thus, improved methods for treating such forms of cancer are needed. Summary of the Invention

[0016] The prior art does not suggest a synergistic effect of the combination of the exemplified antibodies and venetoclax, either alone or in combination, in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia.

[0017] In one aspect, the present disclosure relates to a synergistic combination of an antibody specific for CD19 and a BCL-2 inhibitor, which is useful for the treatment of B-cell malignancies such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and / or acute lymphoblastic leukemia.

[0018] In vitro models are believed to be suggestive of how a compound or combination of compounds will behave in humans.

[0019] MEC-1 cells (DSMZ# ACC497) are a chronic B-cell leukemia cell line. This in vitro model of MEC-1 cells suggests how this combination may work in treating chronic lymphocytic leukemia (CLL) in humans.

[0020] Furthermore, when the compounds are combined in vitro, it is expected that the combination will only have additive effects. Surprisingly, the inventors have found that the combination of a particular antibody specific for CD19 and venetoclax is involved in synergistic levels of specific cell killing in vitro compared to the antibody and venetoclax alone. Specifically, the inventors have found that the combination of MOR00208 and venetoclax is involved in synergistic levels of specific cell killing in vitro in MEC-1 cells compared to the antibody and venetoclax alone.

[0021] In summary, the exemplified combination of anti-CD19 antibodies and venetoclax behaved synergistically in models involving CLL. Because CLL is a B cell-related disorder and CD19 is highly expressed on B cells, the exemplified combination is likely to have the same mechanism of action and should behave synergistically in the treatment of other B cell-related disorders, such as ALL and NHL.

[0022] Thus, the combination of the exemplary CD19-specific antibodies and venetoclax should be effective in treating humans with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and / or acute lymphoblastic leukemia. The expected efficacy of the exemplary CD19-specific antibodies and venetoclax combination will be confirmed in clinical trials.

[0023] Because venetoclax and other BCL-2 inhibitors work by inhibiting the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, causing programmed cell death of cells, it is believed that because the mechanisms of action of venetoclax and other BCL-2 inhibitors are similar, synergy should be seen when treating humans with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and / or acute lymphoblastic leukemia with combinations of exemplary anti-CD19 antibodies and BCL-2 inhibitors other than venetoclax.

[0024] Because the exemplified anti-CD19 antibodies and other anti-CD19 antibodies bind to CD19, it is believed that synergy should also be seen when combining any anti-CD19 antibody and a BCL-2 inhibitor, such as venetoclax, to treat humans with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and / or acute lymphoblastic leukemia.

[0025] An embodiment of the present disclosure includes a combination in which an antibody specific for CD19 comprises an HCDR1 region of sequence SYVMH (SEQ ID NO:1), an HCDR2 region of sequence NPYNDG (SEQ ID NO:2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO:3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO:4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO:5) and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO:6) and venetoclax. In an embodiment, the combination has a synergistic effect. In a preferred embodiment, the combination is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia. [Brief description of the drawings]

[0026] [Figure 1] Figure 1 shows the cytotoxicity of the combination of MOR00208 and venetoclax in the MEC-1 cell line. MEC-1 cells were pretreated with venetoclax for 24 hours. [Diagram 2] Figure 2 shows the cytotoxicity of the combination of MOR00208 and venetoclax in the MEC-1 cell line. MEC-1 cells were pretreated with venetoclax for 24 hours. [Diagram 3] Figure 3 shows the cytotoxicity of the combination of MOR00208 and venetoclax in the MEC-1 cell line. MEC-1 cells were pretreated with venetoclax for 24 hours. [Figure 4] FIG. 4 shows the amino acid sequence of the variable domain of MOR00208. [Diagram 5] FIG. 5 shows the amino acid sequence of the Fc region of MOR00208. [Figure 6] FIG. 6 shows Chou-Talay Combination Index curves of MOR00208 and venetoclax in MEC-1 cell line. [Figure 7] FIG. 7 shows the Chou-Talay combination coefficient curves of MOR00208 and venetoclax in MEC-1 cell line. [Figure 8] FIG. 8 shows the Chou-Talay combination coefficient curves of MOR00208 and venetoclax in MEC-1 cell line. [Figure 9]FIG. 9 shows that MOR00208 in combination with ABT-199 demonstrated superior inhibition of tumor growth compared to either monotherapy in the scToledo SCID mouse model. Group mean values ​​± standard error of the mean (SEM) are depicted. Asterisks indicate statistical significance of tumor doubling time of combination treatment versus MOR0028 or respective ABT-199 treatment alone: ​​*p value < 0.05, **p value < 0.01 and ****p value < 0.0001. Treatment was initiated at randomization with a median tumor volume of 266 mm3 (range 123-406 mm3) 23 days after tumor injection. MOR00208 (11 mg / kg) was administered twice weekly by intraperitoneal injection (ip). ABT-199 (20 or 40 mg / kg) was administered orally (po) daily. [Figure 10] Figure 10 shows that MOR00208 in combination with ABT demonstrated superior median survival of tumor growth compared to either monotherapy in the scToledo SCID mouse model. Kaplan-Meier curves illustrate survival from randomization to the humane endpoint (tumor volume 2000 mm3). Treatment began at randomization with a median tumor volume of 266 mm3 (range 123-406 mm3), 23 days after tumor injection. MOR00208 (11 mg / kg) was administered twice weekly by intraperitoneal injection (ip). ABT-199 (20 or 40 mg / kg) was administered orally (po) daily. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0027] "Synergy," "cooperation," or "synergistic" means more than the expected additive effect of a combination. For in vitro studies, the "synergy," "cooperation," or "synergistic" effect of a combination is determined herein by the methods of Chou et al., Clarke et al., and / or Webb et al. See Ting-Chao Chou, Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies, Pharmacol Rev 58:621-681 (2006), which is incorporated by reference in its entirety. See also Clarke et al., Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models, Breast Cancer Research and Treatment 46:255-278 (1997), which is incorporated by reference in its entirety. See also Webb, JL (1963) Enzyme and Metabolic Inhibitors, Academic Press, New York, which is incorporated by reference in its entirety.

[0028] The term "antibody" refers to monoclonal antibodies including any isotype, such as IgG, IgM, IgA, IgD and IgE. IgG antibodies consist of two identical heavy chains and two identical light chains linked by disulfide bonds. The heavy and light chains each contain a constant region and a variable region. Each variable region contains three segments called "complementarity determining regions" ("CDRs") or "hypervariable regions" that are primarily responsible for binding to an epitope of an antigen. They are numbered sequentially from the N-terminus and are called CDR1, CDR2 and CDR3. The more highly conserved parts of the variable regions outside the CDRs are called "framework regions". "Antibody fragment" refers to Fv, scFv, dsFv, Fab, Fab', F(ab')2 fragments or other fragments containing at least one variable heavy chain or variable light chain, respectively, containing CDRs and framework regions.

[0029] Bcl-2 (B cell lymphoma 2), encoded by the human BCL2 gene, is the first member of the Bcl-2 family of regulator proteins that regulate cell death (apoptosis) by either inducing apoptosis (proapoptotic) or inhibiting apoptosis (antiapoptotic). Bcl-2 is referenced by the NCBI gene number 596. Bcl-2 is considered a particularly important antiapoptotic protein and is therefore classified as an oncogene. The name Bcl-2 is derived from B cell lymphoma 2, as Bcl-2 is the second member of a series of proteins originally described in a chromosomal translocation involving chromosomes 14 and 18 in follicular lymphoma. Orthologues (such as Bcl2 in mouse) have been identified in many mammals for which complete genomic data are available.

[0030] "BCL-2 inhibitors" are a class of drugs that function by inhibiting the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, causing programmed cell death of cells. BCL-2 inhibitors include venetoclax, which is marketed by Abbvie and Genentech (under the trade name VENCLEXTA™, also known as GDC-0199, ABT-199 and RG7601). Venetoclax is currently labeled for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as found by an FDA-approved test, who have received at least one prior therapy. The formula for venetoclax is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl}-1-piperazinyl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide and has the following structure: TIFF2024167208000002.tif68161

[0031] "Venetoclax," "ABT," and "ABT-199" are used synonymously herein.

[0032] Other BCL-2 inhibitors include: Genasense: The antisense oligonucleotide drug Genasense (G3139) was developed by Genta Incorporated to target Bcl-2. The antisense DNA or RNA strand is non-coding and complementary to the coding strand (a template for producing RNA or protein, respectively). Antisense drugs are short sequences of RNA that hybridize with mRNA, inactivating it and preventing protein from being formed. Human lymphoma cell growth (with the t(14;18) translocation) can be inhibited by antisense RNA that targets the start codon region of Bcl-2 mRNA. In vitro studies led to the identification of Genasense, which is complementary to the first 6 codons of Bcl-2 mRNA. These performed well in phase I / II trials in lymphoma. A large phase III trial was initiated in 2004. As of 2016, the drug is not approved and its development company has gone bankrupt.

[0033] ABT-737 and ABT-263: In the mid-2000s, Abbott Laboratories developed a novel inhibitor of Bcl-2, Bcl-xL and Bcl-w known as ABT-737. This compound is part of a group of BH3 mimetic small molecule inhibitors (SMIs) that target these Bcl-2 family proteins but not A1 or Mcl-1. ABT-737 is superior to previous BCL-2 inhibitors given its higher affinity for Bcl-2, Bcl-xL and Bcl-w. In vitro studies have shown that primary cells from patients with B-cell malignancies are sensitive to ABT-737. In animal models, ABT-737 improves survival, causes tumor regression and cures a high percentage of mice. In preclinical studies utilizing patient xenografts, ABT-737 has shown efficacy in treating lymphoma and other hematological cancers. Due to its unfavourable pharmacological properties, ABT-737 is not suitable for clinical trials, whereas its derivative ABT-263 has similar activity against small cell lung cancer (SCLC) cell lines and is in clinical trials.

[0034] "VH" refers to the variable region of the immunoglobulin heavy chain of an antibody or antibody fragment. "VL" refers to the variable region of the immunoglobulin light chain of an antibody or antibody fragment.

[0035] The term "CD19" refers to the protein known as CD19, which has the following synonyms: B4, B lymphocyte antigen CD19, B lymphocyte surface antigen B4, CVID3, differentiation antigen CD19, MGC12802, and T cell surface antigen Leu-12.

[0036] Human CD19 has the following amino acid sequence: TIFF2024167208000003.tif64170

[0037] "MOR00208" is an anti-CD19 antibody. The amino acid sequences of the variable domains are set forth in FIG. 4. The amino acid sequences of the heavy and light chain Fc regions of MOR00208 are shown in FIG. 5. "MOR00208" and "XmAb 5574" are used synonymously to refer to the antibody shown in FIGS. 4 and 5. The MOR00208 antibody is described in U.S. Patent Application Publication No. 12 / 377,25, which is incorporated by reference in its entirety.

[0038] US Patent Application Publication No. 12 / 377,25 describes an antibody designated 4G7 H1.52 Hybrid S239D / I332E / 4G7 L1.155 as follows (later designated MOR00208). >4G7 H1.52 Hybrid S239D / I332E TIFF2024167208000004.tif56170>4G7 L1.155 TIFF2024167208000005.tif28170

[0039] Additional antibodies specific for CD19 are described in U.S. Pat. No. 7,109,30 (Immunomedics), which is incorporated in its entirety by reference; U.S. Pat. App. Pub. No. 11 / 917,75 (Medarex), which is incorporated in its entirety by reference; U.S. Pat. App. Pub. No. 11 / 852,10 (Medimmune), which is incorporated in its entirety by reference; U.S. Pat. App. Pub. No. 11 / 648,50 (Merck Patent GmbH), which is incorporated in its entirety by reference; U.S. Pat. No. 7,968,68 (Seattle Genetics), which is incorporated in its entirety by reference; and U.S. Pat. App. Pub. No. 12 / 710,44 (Glenmark Pharmaceuticals), which is incorporated in its entirety by reference.

[0040] "Fc region" means the constant region of an antibody, which in humans may be IgG1, 2, 3, 4 subclass or other constant region. The sequences of human Fc regions are available at IMGT, Human IGH C-REGIONs, http: / / www.imgt.org / IMGTrepertoire / Proteins / protein / human / IGH / IGHC / Hu_IGHCallgenes.html (retrieved May 16, 2011).

[0041] "RefmAb33" is an antibody whose amino acid sequence is as follows: Heavy chain containing the Fc region: TIFF2024167208000006.tif40170Light chain containing the Fc region: TIFF2024167208000007.tif24170

[0042] RefmAb33 is specific for RSV and shares the same Fc region as MOR00208, and is therefore used as an isotype control.

[0043] "Combination" means two or more items, e.g., a compound, such as an antibody and venetoclax.

[0044] The present disclosure further relates to combinations, medicaments and pharmaceutical compositions comprising the described combinations. The two components of the combination of the present invention, such as an antibody specific for CD19 and venetoclax, can be administered physically or temporally together, simultaneously, separately or sequentially.

[0045] Venetoclax is currently taken orally and administered once daily, while MOR00208 is currently administered intravenously once a week or once every two weeks.

[0046] Preferably, administration of both agents allows both agents to be effective in the patient simultaneously. For example, when MOR208 is administered once a week and venetoclax is administered once a day, the active substances of both agents are present in the patient at the same time. In one embodiment, venetoclax is administered before and / or separately from the administration of the antibody specific for CD19, such as MOR00208.

[0047] Concurrently means that the two components are administered when both components (drugs) are available to the patient at the same time. "Synergism" means that both drugs are available to the patient at the same time.

[0048] Administered together can mean administered at the same time.

[0049] The components of the combination may be formulated in different pharmaceutical compositions. The pharmaceutical composition includes an active agent, such as an antibody for use in human therapy. The pharmaceutical composition may include an acceptable carrier or excipient.

[0050] "Administered" or "administration" includes, but is not limited to, delivery in an injectable form, such as, for example, intravenous, intramuscular, intradermal or subcutaneous routes, or mucosal routes, delivery as a nasal spray or aerosol for inhalation, or delivery as an ingestible solution, capsule or tablet.

[0051] A "therapeutically effective amount" of a compound or combination refers to an amount sufficient to cure, alleviate, or partially prevent the clinical symptoms of a given disease or disorder and its complications. The amount that is effective for a particular therapeutic purpose will vary depending on the severity of the disease or injury as well as the weight and general condition of the subject. It will be understood that the determination of the appropriate dosage can be accomplished by constructing a matrix of values ​​using routine experimentation and testing various points within the matrix. All of these are within the ordinary skill of a trained physician or clinical scientist.

[0052] "Cross-competition" refers to the ability of an antibody or other binding agent to interfere with the binding of another antibody or binding agent to CD19 in a standard competitive binding assay. The ability or extent to which an antibody or other binding agent can interfere with the binding of another antibody or binding molecule to CD19, and therefore whether it can be cross-competed according to the present invention, can be determined using standard competitive binding assays. One suitable assay uses Biacore technology (e.g., by using a BIAcore 3000 instrument (Biacore, Uppsala, Sweden)), which can measure the degree of interaction using surface plasmon resonance technology. Another assay for measuring cross-competition uses an ELISA-based approach. A high-throughput process for "epitope binning" antibodies based on their cross-competition is described in WO 2003 / 48731.

[0053] The term "epitope" includes any protein determinant capable of specific binding to an antibody or otherwise interacting with a molecule. Epitope determinants generally consist of chemically active surface groupings of molecules such as amino acids or carbohydrate or sugar side chains and may have specific three-dimensional structural characteristics and specific charge characteristics. Epitopes may be "linear" or "conformational". The term "linear epitope" refers to an epitope in which all of the points of interaction between the protein and the interacting molecule (such as an antibody) occur linearly along the primary amino acid sequence of the protein (continuous). The term "conformational epitope" refers to an epitope in which discontinuous amino acids are grouped together in a three-dimensional structure. In a conformational epitope, the points of interaction occur across amino acid residues that are spaced apart from one another on the protein.

[0054] "Binds to the same epitope" refers to the ability of an antibody or other binding agent to bind to the same epitope as CD19 and the exemplified antibody. The epitopes of the exemplified antibodies and other antibodies to CD19 can be determined using standard epitope mapping techniques. Epitope mapping techniques are well known in the art, including Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66 (Glenn E. Morris, Ed., 1996) Humana Press, Totowa, New Jersey. For example, linear epitopes can be determined, for example, by simultaneously synthesizing large amounts of peptides corresponding to a portion of a protein molecule on a solid support and reacting the peptides with an antibody while the peptides are still bound to the support. Such techniques are known in the art and are described, for example, in U.S. Patent No. 4,708,87; Geysen et al, (1984) Proc. Natl. Acad. Sci. USA 8:3998-4002; Geysen et al, (1985) Proc. Natl. Acad. Sci. USA 82:78-182; Geysen et al, (1986) Mol. Immunol. 23:709-715. Similarly, conformational epitopes are easily identified by determining the spatial structure of amino acids, for example, by hydrogen / deuterium exchange, X-ray crystallography and two-dimensional nuclear magnetic resonance. See, for example, Epitope Mapping Protocols, supra. Antigenic regions of proteins can also be identified using standard antigenicity and hydropathy plots, such as those calculated using the Omiga version 1.0 software program available from the Oxford Molecular Group.This computer program utilizes the Hopp / Woods method, Hopp et al, (1981) Proc. Natl. Acad. Sci USA 78:3824-3828, for determining antigenic profiles and the Kyte-Doolittle technique, Kyte et al, (1982) J. Mol. Biol. 157:105-132, for hydropathy plots.

[0055] Embodiment An aspect of the present disclosure is a combination comprising an antibody specific for CD19 and a BCL-2 inhibitor for use in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia. In an embodiment, the combination is synergistic.

[0056] The combination of the exemplified anti-CD19 antibody and venetoclax behaves synergistically in an in vitro model related to CLL. Because CLL is a B cell-related disorder and CD19 is highly expressed on B cells, the exemplified combination should have the same mechanism of action and should behave synergistically in the treatment of other B cell-related disorders, such as ALL and NHL. Therefore, the exemplified combination of the CD19-specific antibody and venetoclax should be effective in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia in humans. The expected efficacy of the exemplified combination of the CD19-specific antibody and venetoclax will be confirmed in clinical trials.

[0057] Chronic B-cell leukemia cell line MEC-1 cells (DSMZ# ACC497) were tested. This in vitro model of MEC-1 cells suggests how this combination may work in treating chronic lymphocytic leukemia (CLL) in humans. The Chou index values ​​show a clear synergistic effect of the combination of MOR00208 and venetoclax in specific killing of MEC-1 cells compared to MOR00208 and venetoclax alone.

[0058] In summary, the exemplified combination of anti-CD19 antibodies and venetoclax behaves synergistically in models relevant to CLL.

[0059] Thus, the combination of the exemplary CD19-specific antibodies and venetoclax should be effective in treating humans with non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia.

[0060] Because the mechanisms of action of venetoclax and other BCL-2 inhibitors are similar, it is believed that synergy should be seen when combining an exemplary anti-CD19 antibody and a BCL-2 inhibitor other than venetoclax to treat humans with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and / or acute lymphoblastic leukemia.

[0061] The exemplified anti-CD19 antibodies and other anti-CD19 antibodies bind to CD19 and may be used in a variety of applications, including, for example, U.S. Patent Application Publication No. 12 / 377,25 (Xencor), WO 2005012493, WO 2010053716 (Immunomedics); WO 2007002223 (Medarex); WO 2008022152 (Xencor); WO 2008031056 (Medimmune); WO 2007 / 076950 (Merck Patent GmbH); WO 2009 / 052431 (Seattle Genetics); and WO 2010095031 (Glenmark), all of which are incorporated by reference in their entirety. It is believed that synergy should also be seen when a combination of any of the anti-CD19 antibodies described in Fischer, Inc. (Franklin, MD) and a B-cell lymphoma-2 (Bcl-2) protein inhibitors is used to treat humans with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and / or acute lymphoblastic leukemia.

[0062] In embodiments, antibodies specific for CD19 include antibodies that cross-compete with an antibody comprising an HCDR1 region of the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of the sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of the sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of the sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of the sequence MQHLEYPIT (SEQ ID NO: 6).

[0063] In embodiments, antibodies specific for CD19 include antibodies that bind to the same epitope as an antibody comprising an HCDR1 region of the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of the sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of the sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of the sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of the sequence MQHLEYPIT (SEQ ID NO: 6).

[0064] In an embodiment, the antibody specific for CD19 comprises an HCDR1 region of the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of the sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of the sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of the sequence RMSNLNS (SEQ ID NO: 5) and an LCDR3 region of the sequence MQHLEYPIT (SEQ ID NO: 6).

[0065] In an embodiment, the antibody specific for CD19 has cytotoxic activity. In an embodiment, the antibody specific for CD19 comprises a constant region having ADCC inducing activity. In an embodiment, the antibody specific for CD19 induces ADCC.

[0066] In embodiments, the antibody specific for CD19 induces ADCC and comprises an HCDR1 region of the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of the sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of the sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of the sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of the sequence MQHLEYPIT (SEQ ID NO: 6).

[0067] In an embodiment, the antibody specific for CD19 comprises an HCDR1 region of the sequence SYVMH (sequence number 1), an HCDR2 region of the sequence NPYNDG (sequence number 2), an HCDR3 region of the sequence GTYYYGTRVFDY (sequence number 3), an LCDR1 region of the sequence RSSKSLQNVNGNTYLY (sequence number 4), an LCDR2 region of the sequence RMSNLNS (sequence number 5), and an LCDR3 region of the sequence MQHLEYPIT (sequence number 6), and a constant region having ADCC inducing activity.

[0068] In embodiments, the antibody specific for CD19 has the sequence Variable heavy chain and sequence of TIFF2024167208000008.tif23170 Contains the variable light chain of TIFF2024167208000009.tif15170.

[0069] In certain embodiments, the antibody has the sequence Contains the heavy chain constant domain of TIFF2024167208000010.tif42170.

[0070] In embodiments, the antibody specific for CD19 has the sequence Contains the light chain constant domain of TIFF2024167208000011.tif16170.

[0071] In an embodiment, the BCL-2 inhibitor is venetoclax.

[0072] In embodiments, the components of the combination, the antibody specific for CD19 and venetoclax, are administered separately. In one embodiment, venetoclax is administered prior to administration of the antibody specific for CD19.

[0073] In an embodiment, the components of the combination are administered when both components (agents) are effective in the patient at the same time. "Synergistic" means that both agents are effective in the patient at the same time. In an embodiment, the components of the combination are administered together physically or temporally, simultaneously, separately or sequentially. In an embodiment, the components of the combination are administered simultaneously.

[0074] In embodiments, the combination is a pharmaceutical composition. In embodiments, the composition includes an acceptable carrier. In embodiments, the combination is administered in an effective amount.

[0075] An embodiment of the disclosure includes an antibody specific for CD19 comprising an HCDR1 region of the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of the sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of the sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of the sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of the sequence MQHLEYPIT (SEQ ID NO: 6) for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia, wherein the antibody is used in synergistic combination with venetoclax.

[0076] Aspects of the disclosure include an antibody specific for CD19 comprising an HCDR1 region of the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of the sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of the sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of the sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of the sequence MQHLEYPIT (SEQ ID NO: 6) for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and / or acute lymphoblastic leukemia, wherein the antibody is used in combination with venetoclax. In one embodiment, the antibody is administered in combination with venetoclax. In another embodiment, the antibody is used in combination with venetoclax, and the antibody and venetoclax are administered separately. In a further embodiment, the antibody is administered prior to venetoclax. In a further embodiment, venetoclax is administered prior to the antibody.

[0077] Aspects of the disclosure include a synergistic combination of an antibody specific for CD19 comprising an HCDR1 region of sequence SYVMH (SEQ ID NO:1), an HCDR2 region of sequence NPYNDG (SEQ ID NO:2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO:3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO:4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO:5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO:6) with venetoclax for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia. In embodiments, the non-Hodgkin's lymphoma is selected from the group consisting of follicular lymphoma, small lymphocytic lymphoma, mucosa-associated lymphoid tissue, marginal zone, diffuse large B cell, Burkitt's cell, and mantle cell.

[0078] In an embodiment, the non-Hodgkin's lymphoma is a follicular lymphoma. In an embodiment, the non-Hodgkin's lymphoma is a small lymphocytic lymphoma. In an embodiment, the non-Hodgkin's lymphoma is a mucosa-associated lymphoid tissue. In an embodiment, the non-Hodgkin's lymphoma is a marginal zone lymphoma. In an embodiment, the non-Hodgkin's lymphoma is a diffuse large B-cell lymphoma. In an embodiment, the non-Hodgkin's lymphoma is a Burkitt's lymphoma. In an embodiment, the non-Hodgkin's lymphoma is a mantle cell lymphoma.

[0079] In an embodiment, the combination is for the treatment of chronic lymphocytic leukemia.In an embodiment, the combination is for the treatment of acute lymphoblastic leukemia.

[0080] Another aspect includes a method of treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and / or acute lymphoblastic leukemia in an individual in need of such treatment, comprising administering an antibody specific for CD19 and a BCL-2 inhibitor. In an embodiment of the method, the antibody specific for CD19 includes an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6). In an embodiment of the method, the antibody includes an exemplary antibody specific for CD19. In an embodiment of the method, the BCL-2 inhibitor is venetoclax.

[0081] Another embodiment includes the use of an antibody specific for CD19 comprising an HCDR1 region of the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of the sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of the sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of the sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of the sequence MQHLEYPIT (SEQ ID NO: 6) in the manufacture of a medicament for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia, in synergistic combination with venetoclax. EXAMPLES

[0082] Example 1: Cytotoxicity of MOR00208 and Venetoclax Alone and in Combination in MEC-1 Cells material Tested cell lines: MEC-1 cells (DSMZ# ACC497). Culture conditions of the cell lines used were according to the supplier's information. Cell culture media: Iscove's Modified Dulbecco's Medium (IMDM), Invitrogen, Catalog Number: 31980; RPMI1640, Invitrogen, Catalog Number: 31870; GlutaMAX, Invitrogen, Catalog Number: 35050; FCS: Sigma Catalog Number: F7524 Lot Number: 111M3396. NK: RPMI1640 with GlutaMAX, Invitrogen, Catalog No: 31870, 10% FCS; Biocoll: Biochrome AG Catalog No: L6115 Lot No: 0034D; MACS NK Cell Isolation Kit: Miltenyi Biotec Catalog No: 130-092-657 Lot No: 5150402327; Venetoclax: Selleck Chem. Catalog No: S8048 Lot No: S804803; FCS: Sigma Catalog No: F7524 Lot No: 111M3396; and RefmAb33 (anti-RSV) which contains the same Fc region as MOR00208.

[0083] method The cytotoxic potential of MOR00208 and venetoclax alone and in combination was tested on MEC-1 cell line (CLL). Target cell killing is measured using the following parameters: venetoclax alone treatment at concentrations of 3 μM, 6.5 μM and 10 μM; MOR00208 alone treatment at concentrations of 0.01 pM, 0.1 pM, 1 pM, 10 pM, 100 pM and 10 nM and combination treatment at the listed venetoclax and MOR00208 concentrations. The following: RefmAb33, NK cells alone, MEC-1 cells alone or DMSO are used as controls. In the venetoclax alone and MOR00208 + venetoclax combination groups, target cells are pretreated with venetoclax or DMSO control for 24 hours followed by removal of dead cells prior to the ADCC assay. A dead cell removal kit was used to remove cells killed due to the cytotoxic effect of venetoclax. A dead cell removal kit was performed to mimic the removal of dead cells that also occurs in vivo and to prevent false-negative interference of dead cells in the subsequent ADCC assay. For the ADCC assay, target cells were counted and stained with CFSE at a final concentration of 1 μg / mL. For the control group, i.e., DMSO-treated target cells, the effector:target (E:T) cell ratio was adjusted to 2:1, i.e., 1 × 10E6 / mL effector cells (NK cells) and 5 × 10E5 / mL target cells (MEC-1 cells). For the venetoclax alone group and MOR00208 + venetoclax combination group, the number of target cells decreased in accordance with the cytotoxic effect of venetoclax observed during the 24-hour treatment, while the number of effector cells increased to 1 × 10 6The concentration of DAPI in each well was kept constant at 1 μg / mL. The ADCC assay was performed as follows: 96-well plates were used, and 100 μL of MEC-1 target cell suspension was added to each well, followed by 100 μL of NK effector cell suspension. The mixed cell suspension was centrifuged and resuspended in 100 μL of medium containing antibody or corresponding control solution. Antibodies were diluted in medium to a range of 10 nM to 0.01 pM (corresponding to 1.5 μg / mL to 1.5 pg / mL). The ADCC assay was incubated for 2 h at 37 °C in a CO2 incubator. After 10 min of incubation on ice, 50 μL of DAPI solution was added to each well (final concentration 1 μg / mL) and incubated for another 10 min on ice. The ADCC measurement was performed using a BD FACSVerse instrument. Dead target cells were determined as DAPI-positive cells.

[0084] data A total of three independent experiments were performed to determine the cytotoxic potential of the combination of MOR00208 and venetoclax. Tables of individual raw data from all three experiments are shown in Tables 1-6. Individual ADCC dose-response curves from all three experiments are shown in Figures 1-3. Mean (+ / - SEM) combination coefficient curves from all three experiments for each venetoclax concentration are shown in Figures 6-8.

[0085] Test 1: TIFF2024167208000012.tif81170TIFF2024167208000013.tif180170

[0086] Test 2: TIFF2024167208000014.tif78170TIFF2024167208000015.tif179170

[0087] Test 3: TIFF2024167208000016.tif76170TIFF2024167208000017.tif181170

[0088] Calculating synergy Combination index (CI) calculations are completed to determine the synergy of the exemplary anti-CD19 antibody and venetoclax combinations compared to MOR00208 and venetoclax alone. Such calculations are described in Ting-Chao Chou, Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies, Pharmacol Rev 58:621-681 (2006), which is incorporated by reference in its entirety, and in Chou TC, Talalay P, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55 (1984), which is incorporated by reference in its entirety. The Chou-Talalay method is performed using the CI-isobol method.

[0089] Median effect equation The half-effect equation is a formula that expresses the effect of an inhibitor (such as a drug) as F a / F u =(D / D50)^m, where D is the dose and F a and F u is the proportion of systems affected or not affected by dose D (F a +F u =1); D50 is the dose that exerts half the effect (e.g., IC50, ED50, LD50). The constant m determines the shape of the dose-response curve. We performed nonlinear regression calculations using GraphPad Prism to estimate the parameters m and D50.

[0090] CI-isobol method The CI-isobol method provides a quantitative assessment of synergy between drugs. The combination index (CI) is estimated from the dose-effect data of single and combined drug treatments. A CI < 1 indicates synergy; CI = 1 indicates additivity; and CI > 1 indicates antagonism. The more significant the drug interaction (synergy or antagonism), the more divergent the CI value is from 1. Formally, the combination index (CI) of a combined drug treatment is given by CI = D1 / D x1 +D2 / D x2 where D1 and D2 are the doses of drug 1 and drug 2 in the combination, respectively; Dx1 and Dx2 are the doses of treatment with only drug 1 and drug 2 that are believed to give the same effect as the combination effect. The doses Dx1 and Dx2 must be estimated from the dose-effect data of the single drug treatments. Essentially, a median effect equation is fitted to the data for each drug. From the median effect equation for the drug, we can estimate the dose (i.e., D) required to exert the effect (i.e., Fa, Fu). The further a point is from the line of additive effect, the greater the difference between 1 and its CI, and therefore the stronger the effect (synergistic or antagonistic).

[0091] result The mean (+ / - SEM) combination coefficient curves of all three experiments per venetoclax concentration are shown in Figures 6-8. The combination coefficient values ​​show a clear synergy of the combination of MOR00208 and venetoclax in the specific killing of MEC-1 cells compared to MOR00208 and venetoclax alone. Very low doses of MOR00208 have little or no effect in the illustrated ADCC cell killing assay. Thus, the CI values ​​of very low doses of MOR00208 show values ​​of 1 or slightly above 1, which represent the activity of venetoclax alone. At MOR00208 concentrations where MOR00208 alone shows normal cell killing activity, a clear synergy is shown by the CI values ​​of less than 1, which represent the activity of MOR00208 and venetoclax. The highest concentration of MOR00208 exemplified herein has been obtained in an ongoing clinical trial where MOR00208 is administered once weekly at 12 mg / kg. Therefore, the illustrated in vitro models are believed to be predictive of activity in humans. Therefore, the combination of MOR00208 and venetoclax should also behave synergistically in the treatment of human non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).

[0092] It will be understood that the present description, specific examples and data, while indicating exemplary embodiments, are presented by way of illustration and are not intended to limit the invention. Various changes and modifications in the invention will become apparent from the discussion, disclosure and data contained herein and are therefore considered a part of the invention.

[0093] Example 2: Efficacy of MOR00208 in combination with ABT-199 in a human subcutaneous lymphoma cell xenograft model in SCID mice The efficacy benefit of MOR00208 in combination with venetoclax (ABT-199) was further investigated in a SCID mouse model of human subcutaneous TOLEDO lymphoma cell tumors. Tumor growth and mortality were assessed.

[0094] material and method Toledo cell line and culture medium were purchased and kindly provided by Oncodesign. Tumor cells were grown as monolayers at 37°C in a humidified atmosphere (5% CO2, 95% air). Culture medium was RPMI 1640 with 2 mM L-glutamine (ref: BE12-702F, Lonza, Verviers, Belgium) supplemented with 10% fetal bovine serum (ref: P30-1506, Lonza), HBSS (ref: BE10-543F), glucose (ref: G8769, Sigma, France), Hepes (ref: BE17-737E, Lonza) and sodium pyruvate (ref: BE13-115E, Lonza). Cells are attached to plastic flasks. For experimental use, tumor cells were detached from culture flasks by treatment with trypsin-versene (ref: BE02-007E, Lonza) for 5 min in Hanks medium without calcium or magnesium (ref: BE10-543F, Lonza) and neutralized by addition of complete culture medium. Cells were counted using a hemocytometer and their viability was assessed by 0.25% trypan blue exclusion assay.

[0095] Tumors were grown using 10 × 10 Toledo cells in 200 μl of RPMI 1640 containing Matrigel (50:50, v:v, ref: 356237, BD Biosciences, France). 6 Tumors were induced in SCID mice by subcutaneous injection into the right flank area. Tumors had a mean volume of 256±68 mm 3 On day 23 of the study, 60 mice were randomized into 6 groups of 10 animals each according to their individual tumor volumes using Vivo Manager® software (Biosystemes, Couternon, France). Statistical tests (analysis of variance, ANOVA) were performed to examine the homogeneity between groups. MOR208 was injected intraperitoneally (IP) into the peritoneal cavity of the mice. The combined substances were administered by oral gavage (per os, PO) via stomach tube.

[0096] The treatment schedule, beginning on day 23, was as follows:

[0097] Animals in Group 1 received PEP PO once daily and a single IP injection of PBS twice weekly.

[0098] Group 2 animals received ABT-199 PO daily at 20 mg / kg / adm.

[0099] Group 3 animals received ABT-199 PO daily at 40 mg / kg / adm.

[0100] Animals in Group 4 received a single IP injection of MOR208 at 11 mg / kg / inj on days 23, 27, 30, 34, 37 and 41, followed by a single IP injection of MOR208 at 11 mg / kg / inj on day 48 (twice weekly).

[0101] Group 5 animals received ABT-199 PO at 20 mg / kg / adm daily in combination with IP injections of MOR208 at 11 mg / kg / inj on days 23, 27, 30, 34, 37, and 41, and on days 48, 51, 55, and 58.

[0102] Group 6 animals received ABT-199 PO at 40 mg / kg / adm daily in combination with two cycles of a single IP injection of MOR208 at 11 mg / kg / inj on days 23, 27, 30, 34, 37, and 41, and on days 48, 51, 55, and 58.

[0103] All study data, including animal weight measurements, clinical and mortality records, and treatments, were scheduled and recorded in the Vivo Manager® database (Biosystemes, Dijon, France). Survival and behavior were recorded daily. Body weights and tumor volumes were measured twice weekly. Tumor length and width were measured twice weekly with calipers, and tumor volumes were calculated using the formula: Estimated from TIFF2024167208000018.tif19161.

[0104] result Combination treatment of MOR00208 and ABT-199 at doses of 20 mg / kg and 40 mg / kg resulted in superior and statistically significant inhibition of Toledo lymphoma cell growth compared to vehicle control and both monotherapy regimens. Analysis of mouse survival from randomization to humane endpoint (tumor volume 2000 mm3) indicates that the antitumor effect of MOR00208 in combination with ABT-199 is even more pronounced. The median survival and respective lifespan extension of the combination group was superior compared to each monotherapy. Further characterization of the combination effect has resulted in the MOR00208 combination outcome being classified as synergistic since the effect of the combination is greater than the sum of each monotherapy (Figure 9, Table 7, Figure 10, Table 8). TIFF2024167208000019.tif118170TIFF2024167208000020.tif121170

Claims

1. A combination comprising an antibody specific for CD19, the antibody comprising an HCDR1 region comprising the sequence SYVMH (SEQ ID NO:1), an HCDR2 region comprising the sequence NPYNDG (SEQ ID NO:2), an HCDR3 region comprising the sequence GTYYYGTRVFDY (SEQ ID NO:3), an LCDR1 region comprising the sequence RSSKSLQNVNGNTYLY (SEQ ID NO:4), an LCDR2 region comprising the sequence RMSNLNS (SEQ ID NO:5), and an LCDR3 region comprising the sequence MQHLEYPIT (SEQ ID NO:6), and venetoclax, for use in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia.

2. The combination according to claim 1, wherein the antibody has ADCC activity.

3. 3. The combination according to claim 1 or 2, wherein the antibody has the sequence and a variable heavy chain comprising the sequence A combination comprising a variable light chain of

4. 4. The combination according to claim 1, wherein the antibody has the sequence A combination comprising a heavy chain constant domain comprising:

5. 5. The combination according to claim 1, wherein the antibody has the sequence A combination comprising a light chain constant domain comprising:

6. A combination according to any one of claims 1 to 5, characterized in that the antibody specific for CD19 and venetoclax are administered separately.

7. A combination according to any one of claims 1 to 6, characterized in that venetoclax is administered prior to administration of the antibody specific for CD19.

8. A combination according to any one of claims 1 to 7, characterized in that the antibody specific for CD19 and venetoclax are administered simultaneously.

9. A combination according to any one of claims 1 to 8, characterized in that the antibody specific for CD19 and venetoclax are administered when both agents are effective simultaneously in the patient.

10. 10. The combination according to any one of claims 1 to 9, for use in the treatment of chronic lymphocytic leukemia.

11. 11. The combination according to any one of claims 1 to 10, for use in the treatment of acute lymphoblastic leukemia.

12. 12. The combination of any one of claims 1 to 11, for use in the treatment of non-Hodgkin's lymphoma, wherein the non-Hodgkin's lymphoma is selected from the group consisting of follicular lymphoma, small lymphocytic lymphoma, mucosa-associated lymphoid tissue, marginal zone, diffuse large B-cell, Burkitt's cell and mantle cell.

Citation Information

Patent Citations

  • Combination therapy with anti-CD19 antibodies and purine analogs

    JP2014525925A

  • Combination therapy with anti-CD19 antibody and nitrogen mustard

    JP2014525926A

  • Method for treating cancer

    WO2015130585A1